key: cord-0743093-uifnjio5
authors: Wu, Fan; Wang, Aojie; Liu, Mei; Wang, Qimin; Chen, Jun; Xia, Shuai; Ling, Yun; Zhang, Yuling; Xun, Jingna; Lu, Lu; Jiang, Shibo; Lu, Hongzhou; Wen, Yumei; Huang, Jinghe
title: Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
date: 2020-04-06
journal: nan
DOI: 10.1101/2020.03.30.20047365
sha: f4353ce3b4867f67470e99b1bce7908fcb655cec
doc_id: 743093
cord_uid: uifnjio5

Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time. Findings SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus. SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter. The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions. The titers of NAbs were variable in different patients. Elderly and middle-age patients had significantly higher plasma NAb titers (P<0.0001) and spike-binding antibodies (P=0.0003) than young patients. Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively. The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response. Interpretation The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression. The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus. Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment. Funding Ministry of Science and Technology of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission, and Chinese Academy of Medical Sciences

Background 24 The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public 25 health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to 26 correlate with recovery and protection of this disease. However, the characteristics of 27 these antibodies have not been well studied in association with the clinical 28 manifestations in patients.

Plasma collected from 175 COVID-19 recovered patients with mild symptoms were 32 screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization 33 assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, 34 and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2- 35 specific NAbs and the spike-binding antibodies were monitored at the same time. The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may 53 raise the concern about the role of NAbs on disease progression. The correlation of 54 NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the 55 interplay between virus and host immune response in coronavirus infections should be 56 further explored for the development of effective vaccine against SARS-CoV-2 virus. 57 Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for 58 prevention or treatment.

The outbreak of coronavirus disease 2019 in December 2019 has spread 69 around the world and become a global pandemic. 1 The etiological agent of COVID-19 70 was identified as a SARS-related coronavirus designated as SARS-COV-2 71 coronavirus. 2,3 As of March 27, 2020, it had caused a total of 509,164 cases of infection 72 and resulted in 23,335 deaths worldwide. 1 About 81% of infected patients showed only 73 mild symptoms, but 14% of them had severe symptoms such as dyspnea, high 74 respiratory frequency and low blood oxygen saturation. Another 5% of patients, 75 especially those over 60, or with comorbidities, progressed to critical condition. About Here, we used a pseudotyped-lentiviral-vector-based neutralization assay to measure 98 SARS-Cov-2-specific NAbs in plasma from recovered COVID-19 patients with mild 99 symptoms. The pseudovirus (PsV) neutralization assay is a sensitive and reproducible 100 assay. It does not produce any highly pathogenic virus, and it can be safely handled in 101 a biosafety level 2 facility. Herein, we aimed to explore the clinical characteristics the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint ELISA 148 SARS-CoV-2 RBD, S1, or S2 protein and SARS-CoV RBD or S1 protein (1 μg/ml) 149 was coated on a MaxiSorp Nunc-immuno 96-well plate overnight at 4 °C. Wells were 150 blocked with 5% nonfat milk in PBS for 1 hour at room temperature, followed by The median length of hospital stay was 16 days (ranging from 7 to 30 days), and the 177 median disease duration was 21 days (9 to 34 days). 181 We collected five plasma samples from COVID-19 patients at the time of discharge and 182 measured their neutralizing titers against SARS-CoV-2 infection of 293T/ACE2 cells.

All five plasma showed a concentration-dependent inhibition of SARS-CoV-2 PsV 184 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint infection of 293T/ACE2 cells ( Figure 1A ). Plasma with high titers of NAbs showed 185 higher titers of SARS-CoV-2 RBD, S1, and S2-specific binding antibodies ( Figure 1B ). 186 Moreover, plasma from these patients also showed cross-binding to SRAS-CoV RBD 187 and S1 regions ( Figure 1C ), but the binding to SARS-CoV S protein was not consistent We observed that NAb titers were variable in the plasma of 175 recovered patients.

ID50s ranged from below detection limit (<40) to 21567 ( Figure 3A ). About 30% of 224 recovered patients generated a very low level of NAb titers (ID50: < 500) ( Figure 3A , 225 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint 3B, and Supplementary Table 1) , and NAb titers in ten of them were below the limit of 226 detection (ID50: <40), though all of them were lab confirmed infected with SARS-227 CoV-2 (Supplementary Table 2 ). About 17%, 39%, and 14% showed medium-low 228 (ID50: 500-999), medium-high (ID50: 1000-2500), and high (ID50: > 2500) NAb titers, 229 respectively ( Figure 3B ). We also collected and measured the levels of NAbs in plasma 230 from 47 of the 175 patients during the follow-up examination two weeks after discharge.

As shown in Figure 3C 242 We observed that elderly patients were more likely to induce higher titers of NAbs than 243 younger patients. As shown in Figure 4A , the patients were divided into three groups the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint 5A left and right). However, none of the patient progressed into severe conditions, and 267 no significant difference was observed between age and length of hospital stay among 268 these patients ( Figure 4D ). Interestingly, we observed that the NAb titers negatively 269 correlated with blood lymphocyte counts (r= -0.44, p<0.0001, Figure 5B left) and 270 positively correlated with blood CRP levels (r= 0.5, p<0.0001, Figure 5B It is also noteworthy that the levels of NAbs in patients were variable. About 30% of 299 patients failed to develop high titers of NAbs after COVID-19 infection. However, the 300 disease duration of these patients compared to others was similar. Notably, there were 301 ten recovered patients whose NAb titers were very low, under the detectable level of the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint

The NAbs titers in patients were also observed to be correlated with the age of the 308 patients. Elderly patients had significantly higher titers of NAbs than younger patients. antibody therapy, an easy task that can be performed using the PsV neutralization assay.

Correlation of NAbs titers with the age, lymphocyte counts and blood CRP levels of 336 patients also lays the groundwork for further study to explore the mechanism of NAbs 337 development in COVID-19 patients. 340 We declare no competing interests. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint 350 Acknowledgments 351 We want to particularly acknowledge Dr. Shan Lu for reviewing the manuscript. This the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint and S2 (brown), in six COVID-19 patient plasma are shown and compared with the kinetics of NAbs 436 titers (right Y axis, red) in the same patient. (C) The correlations between the SARS-CoV-2 NAbs titers 437

and RBD, S1, or S2 binding antibodies levels of patients were analyzed by Pearson correlation test. 1:400 438 diluted plasma was incubate with RBD, S1, or S2 protein. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is All rights reserved. No reuse allowed without permission.

the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03.30.20047365 doi: medRxiv preprint

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation

A new coronavirus associated with human respiratory 363 disease in China

A pneumonia outbreak associated with a new 365 coronavirus of probable bat origin

Characteristics of and Important Lessons From the 367

COVID-19) Outbreak in China: Summary of a Report of 368 72314 Cases From the Chinese Center for Disease Control and Prevention

On natural and artificial vaccinations

Treatment of severe acute respiratory 373 syndrome with convalescent plasma

Treatment with convalescent plasma for influenza A 375 (H5N1) infection

Evaluation of Convalescent 377 Plasma for Ebola Virus Disease in Guinea

The convalescent sera option for containing COVID-19

Neutralizing antibodies in patients with severe acute 381 respiratory syndrome-associated coronavirus infection

Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 385 Inhibitor

Median Age (Years)

Median NAb titers (ID50)

Median NAb titers (ID50)